- Home
- LQDA vs LBTYK Comparison
LQDA vs LBTYK Comparison
Compare LQDA & LBTYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LQDA | LBTYK |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | 6636 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LQDA | LBTYK |
|---|---|---|
| Price | $42.61 | $11.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $41.00 | N/A |
| AVG Volume (30 Days) | 930.9K | ★ 1.3M |
| Earning Date | 05-08-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $15.41 |
| Revenue Next Year | $57.13 | $3.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $9.66 |
| 52 Week High | $46.67 | $13.12 |
Technical Indicators
Market Signals| Indicator | LQDA | LBTYK |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 50.91 |
| Support Level | $35.00 | $11.43 |
| Resistance Level | $46.67 | $12.23 |
| Average True Range (ATR) | 1.65 | 0.41 |
| MACD | 0.46 | 0.04 |
| Stochastic Oscillator | 92.74 | 54.44 |
Price Performance
Historical ComparisonAbout LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
About LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.